DSpace Home
→
Fakülteler / Faculties
→
Tıp Fakültesi
→
Temel Tıp Bilimleri / Basic Medical Sciences
→
Makale Koleksiyonu
→
Browsing Makale Koleksiyonu by Author

Browsing Makale Koleksiyonu by Author "Güney Eskiler, Gamze"

Now showing items 1-20 of 27

A novel [Mn-2(mu-(C6H5)(2)CHCOO)(2)(bipy)(4)](bipy)(ClO4)(2) complex loaded solid lipid nanoparticles: synthesis, characterization and in vitro cytotoxicity on MCF-7 breast cancer cells

Güney Eskiler, Gamze; G. Cecener; G. Dikmen; I. Kani; U. Egeli; B. Tunca (TAYLOR & FRANCIS, 2016)

Manganese (Mn)-based complexes have been drawing attention due to the fact that they are more effective than other metal complexes. However, the use of Mn(II)-based complexes in medicine remains limited because of certain ...
An in vitro model for the development of acquired tamoxifen resistance

Güney Eskiler, Gamze; Gulsah Cecener; Berrin Tunca; Unal Egeli (SPRINGER, 2016)

The development of resistance to tamoxifen (Tam) remains a challenging clinical problem for ER+ breast cancer patients. To understand the mechanisms underlying of resistance, previous studies have driven the acquisition ...
Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey

G. Cecener; Güney Eskiler, Gamze; Güney Eskiler, Gamze; U. Egeli; B. Tunca; A. Alemdar; S. Gokgoz; I. Tasdelen (SPRINGER, 2016)
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile

Güney Eskiler, Gamze; Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (WILEY, 2019)

The objective of the present study was to elucidate the effect of BMN 673 (talozoparib) on BRCA1 mutant (HCC1937) and wild-type (MDA-MB-231) triple negative breast cancer (TNBC). The in vitro cytotoxicity results indicated ...
Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer

Güney Eskiler, Gamze; Şahin, Elvan; Deveci Özkan, Asuman; Kaleli, Süleyman (ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, 2019)

Curcumin has a therapeutic potential activity through modulation of different signaling pathways in various types of cancer. However, the relationship between the efficacy of curcumin and the homologous recombination (HR) ...
E-Health and Bioengineering Conference

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (IEEE, 2017)

The anti-estrogen tamoxifen (Tam) is the most preferred option for patients with estrogen-receptor (ER)-positive breast cancer. However, multi-drug resistance (MDR) is a considerable clinical problem in the successful ...
E-Health and Bioengineering Conference

Isil Ezgi Eryilmaz; Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (IEEE, 2017)

We mentioned the importance of clinical sequence analysis in risk determination, diagnostic and therapeutic process of familial breast cancer and we also summarized next generation sequencing applications in this cancer ...
IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia

Guney G. Eskiler; Güney Eskiler, Gamze; E. Bezdegumeli; Z. Ozman; Deveci A. Ozkan; Deveci Özkan, Asuman; Bilir, Cemil; Bilir, Cemil; B. N. Kucukakca; M. N. Ince; A. Y. Men; O. Aktas; Y. E. Horoz; D. Akpinar (COMENIUS UNIV, 2019)

CONCLUSION: STAT3 may be considered as a therapeutic target for cachectic patients with gastric, lung and breast cancer. Furthermore, IL-6 mediates STAT3 activation in cachectic gastric and breast cancer patients (Tab. 5, ...
In vitro apoptotic effect of Zinc(II) complex with N-donor heterocyclic ligand on breast cancer cells

Güney Eskiler, Gamze; Ibrahim Kani (WALTER DE GRUYTER GMBH, 2019)

Conclusions: Zn(II) complex has great therapeutic potential for the treatment of breast cancer. However, further studies are warranted to identify the underlying mechanisms of apoptotic cell death and to reduce the toxicity ...
In vitro cytotoxic and antiproliferative effects of usnic acid on hormone-dependent breast and prostate cancer cells

Isil Ezgi Eryilmaz; Güney Eskiler, Gamze; Unal Egeli; Beste Yurdacan; Gulsah Cecener; Berrin Tunca (WILEY, 2018)

The aim of the current study was first to investigate cytotoxic activity of usnic acid (UA) on hormone-dependent breast and prostate cancer, and normal cells. Cells were treated with increasing concentrations (25 to 150 ...
Inhibition of TLR4/TRIF/IRF3 Signaling Pathway by Curcumin in Breast Cancer Cells

Güney Eskiler, Gamze; Deveci Özkan, Asuman; Kaleli, Süleyman; Bilir, Cemil (CANADIAN SOC PHARMACEUTICAL SCIENCES, 2019)

Purpose: Toll-like receptor 4 (TLR4) is over-expressed in breast tumors and thus contributing to the tumor progression and metastasis. Natural products have drawn attention in cancer immunotherapy due to their various ...
Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid

Beste Yurdacan; Unal Egeli; Güney Eskiler, Gamze; Güney Eskiler, Gamze; Isil Ezgi Eryilmaz; Gulsah Cecener; Berrin Tunca (WILEY, 2019)

Objectives Sorafenib (SOR) is an orally administered molecular targeted agent in the systemic chemotherapy of hepatocellular carcinoma (HCC). However, the partial response of SOR is limited due to its adverse side effect ...
Potential role of solid lipid nanoparticles in overcoming the acquired tamoxifen resistance of breast cancer

Gulsah Cecener; Güney Eskiler, Gamze; Unal Egeli; Berrin Tunca (ELSEVIER SCIENCE BV, 2017)
Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer

Güney Eskiler, Gamze (ELSEVIER SCIENCE BV, 2018)

The objective of the present study was to investigate the effect of tamoxifen (Tam) loaded solid lipid nano-particles (SLNs) on MCF7 Tam-resistant breast cancer cells (MCF7-TamR). Tam-SLNs were produced by the hot ...
Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor-positive breast and prostate cancer cells

Güney Eskiler, Gamze; Güney Eskiler, Gamze; Isil Ezgi Eryilmaz; Beste Yurdacan; Unal Egeli; Gulsah Cecener; Berrin Tunca (WILEY, 2019)

The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively. The antiproliferative ...
Synergistic Effects of Nobiletin and Sorafenib Combination on Metastatic Prostate Cancer Cells

Güney Eskiler, Gamze; Deveci Özkan, Asuman; Bilir, Cemil; Kaleli, Süleyman (ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, 2019)

Objective: Herein we, for the first time, investigated a potential synergistic effect of nobiletin (NOB) and sorafenib (SOR) on PC-3 prostate cancer and HUVEC control cell lines.Methods: In order to determine the cytotoxic ...
Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (SPRINGER/PLENUM PUBLISHERS, 2018)

PurposeThe purpose of the study was to produce BMN 673 loaded solid lipid nanoparticles (SLNs) to improve its therapeutic index, to minimize toxicity and to overcome homologous recombination (HR)-mediated resistance.Meth ...
Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In Vitro

Güney Eskiler, Gamze; Güney Eskiler, Gamze; Gulsah Cecener; Gokhan Dikmen; Unal Egeli; Berrin Tunca (BENTHAM SCIENCE PUBL LTD, 2019)

Conclusion: The apoptotic rates in the 10 nM BMN 673-SLNs treatment (88.78% and 85.56%) for 12 days were significantly higher than those in 10 nM BMN 673 (82.6% and 25.86%) for 12 days in HCC1937 and HCC1937-R cells, ...
Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (WILEY, 2020)

Herein, we investigated efflux pumps-mediated talazoparib-resistance in the treatment of triple-negative breast cancer (TNBC). Furthermore, we produced a novel talazoparib-solid lipid nanoparticles (SLNs) and then explored ...
Talazoparib to treat BRCA-positive breast cancer

Güney Eskiler, Gamze (PROUS SCIENCE, SAU-THOMSON REUTERS, 2019)

Talazoparib tosylate (BMN-673, Talzenna; Pfizer) is an oral poly [ADP-ribose] polymerase (PARP) inhibitor (PARPi) that has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) ...